DCOY
NASDAQDecoy Therapeutics Inc.
News25/Ratings1
News · 26 weeks49-9%
2026-04-192026-10-11
Mix3090d
- Insider11(37%)
- Other10(33%)
- SEC Filings9(30%)
Latest news
25 items- SECSEC Form 424B3 filed by Decoy Therapeutics Inc.424B3 - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form S-1 filed by Decoy Therapeutics Inc.S-1 - Decoy Therapeutics Inc. (0001615219) (Filer)
- PRDecoy Therapeutics to Present at The Small Cap ShowcaseCAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City. Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference. Details of the presentation are as follows: Date: Thursday, October 1, 2026Time: 11:30 a.m. ETLocation: New York, NYPresenter: Rick Pierce, Chief Executive Officer of Decoy Therapeu
- PRDecoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV ProgramOnce-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic Coronaviruses: DCOY-CoV is designed to protect against endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2), in people at high risk of serious illness including the more than 20 million high-risk immunocompromised and 15 million COPD patients in the U.S. and Europe. Symposium Showcase: Chief Technology Officer Dr. Michael Lipp presenting initial PK dataset today, September 29 at the Boulder Peptide Symposium's Peptide Showcase. CAMBRIDGE, Mass., Sept. 29, 2026 /PRNews
- SECDecoy Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
- PRDecoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleaseHOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction. The original press release incorrectly stated that the new unregistered warrants to purchase up to 2,368,868 shares of the Company's common stock to be issued in connection with the transaction (the "New Warrants") would become exercisable upon receipt of stockholder approval.The New Warrants are not subject to stockholder approval and will become exercisable immediately upon issuance. The New Wa
- PR/C O R R E C T I O N -- Decoy Therapeutics, Inc/In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher EligibilityCAMBRIDGE, Mass., Sept. 22, 2026
- PRDecoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq RulesHOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of 1,184,434 warrants (the "Existing Warrants"). The Existing Warrants were issued on June 29, 2026 and will be exercised at a reduced exercise price of $3.25 per share. I
- PRToday’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical MineralsDENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ:VKTX) is pushing its VK2735 obesity program toward Phase 3 while exploring less-frequent maintenance dosing; NeOnc Technologies Holdings (NASDAQ:NTHI) is advancing its NEO100 brain-cancer program after encouraging Phase 2a results; Decoy Therapeutics (NASDAQ:DCOY) is expanding its antiviral platform into high-consequence viruses including Ebola; and Greenland Mines Ltd. (NASDAQ:GRML) is seeking to more than double its exploration footprint at the Sarfartoq rare-earth district. Viking Therapeutics The obesity-drug race
- PRDecoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive FundingNext-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher EligibilityCAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval. Based on recent encouraging discussions, the Company is actively pursuing non-d
- SECDecoy Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
- INSIDERDirector Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Decoy Therapeutics Inc.SCHEDULE 13G - Decoy Therapeutics Inc. (0001615219) (Subject)
- SECSEC Form 10-Q filed by Decoy Therapeutics Inc.10-Q - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form DEF 14A filed by Decoy Therapeutics Inc.DEF 14A - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form DEFA14A filed by Decoy Therapeutics Inc.DEFA14A - Decoy Therapeutics Inc. (0001615219) (Filer)
DCOY FAQ
6 questionsWhere does DCOY stock trade?
Decoy Therapeutics Inc. (DCOY) is listed on NASDAQ.What sector and industry is DCOY in?
Decoy Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Decoy Therapeutics Inc. go public?
Decoy Therapeutics Inc. (DCOY) completed its IPO in 2015.What are analysts saying about DCOY?
Decoy Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $250.00 price target on 2026-01-23. Recent price targets cluster around $250.00.What companies are similar to DCOY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DCOY side-by-side with any of them on Quantisnow.How can I track DCOY on Quantisnow?
Quantisnow aggregates Decoy Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DCOY to receive live email and push alerts on every new disclosure.